Impact of cystic fibrosis on pediatric oral health: a comprehensive review
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20250046Keywords:
Pediatric oral health, Enamel erosion, Preventive dentistry, Salivary dysfunctionAbstract
Cystic fibrosis (CF) is a complex genetic disorder that affects multiple systems, including the oral cavity. In children, CF leads to unique challenges in maintaining oral health due to the interplay of systemic factors, dietary requirements, and medical treatments. Alterations in salivary flow and composition, often observed in CF patients, contribute to an increased risk of xerostomia, enamel erosion, and periodontal disease. These issues are further exacerbated by high-calorie, carbohydrate-rich diets prescribed to manage metabolic needs, creating a favorable environment for caries development. The use of inhaled corticosteroids, nebulized antibiotics, and other essential medications introduces additional oral health challenges, such as fungal infections and changes in the oral microbiota. Gastroesophageal reflux disease, a common comorbidity in CF, contributes to dental erosion through repeated exposure to gastric acids. Despite these risks, frequent use of antibiotics in CF patients has shown a paradoxical reduction in dental caries prevalence, highlighting the complex oral microbial dynamics in this population. Preventive strategies include dietary counseling, regular fluoride application, and tailored oral hygiene routines, such as the use of electric toothbrushes and interdental brushes. Therapeutic interventions focus on minimally invasive techniques, fluoride-releasing restorative materials, and the application of sealants to protect vulnerable tooth surfaces. Collaboration among dentists, pediatricians, dietitians, and CF specialists is crucial to address the multifactorial challenges and improve both oral and systemic outcomes. The relationship between cystic fibrosis and oral health underscores the importance of integrating dental care into the broader management of CF. Early identification of oral complications and the implementation of personalized prevention and treatment strategies can significantly enhance the quality of life for pediatric CF patients while reducing the long-term burden of oral diseases.
Metrics
References
Ferrazzano G, Sangianantoni G, Cantile T, Amato I, Orlando S, Ingenito A. Dental enamel defects in Italian children with cystic fibrosis: an observational study. Community Dent Health. 2012;29(1):106-9.
Albilia JB, Lam DK, Blanas N, Clokie CM, Sándor GK. Small mouths… Big problems? A review of scleroderma and its oral health implications. J Canad Dent Assoc. 2007;73(9).
Stanojevic S, Davis SD, Retsch-Bogart G, Webster H, Davis M, Johnson RC, et al. Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. Am J Respir Crit Care Med. 2017;195(9):1216-25. DOI: https://doi.org/10.1164/rccm.201610-2158OC
Nelson LP, Getzin A, Graham D, Zhou J, Wagle EM, McQuiston J, et al. Unmet dental needs and barriers to care for children with significant special health care needs. Pediatr Dent. 2011;33(1):29-36.
Sischo L, Broder H. Oral health-related quality of life: what, why, how, and future implications. J Dent Res. 2011;90(11):1264-70. DOI: https://doi.org/10.1177/0022034511399918
Peker S, Kargul B, Tanboga I, Tunali-Akbay T, Yarat A, Karakoc F, et al. Oral health and related factors in a group of children with cystic fibrosis in Istanbul, Turkey. Niger J Clin Pract. 2015;18(1):56-60. DOI: https://doi.org/10.4103/1119-3077.146980
Sheppard M, Nicholson A. The pathology of cystic fibrosis. Curr Diagnost Pathol. 2002;8(1):50-9. DOI: https://doi.org/10.1054/cdip.2001.0088
Rivas Caldas R, Le Gall F, Revert K, Rault G, Virmaux M, Gouriou S, et al. Pseudomonas aeruginosa and Periodontal Pathogens in the Oral Cavity and Lungs of Cystic Fibrosis Patients: a Case-Control Study. J Clin Microbiol. 2015;53(6):1898-907. DOI: https://doi.org/10.1128/JCM.00368-15
Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-51. DOI: https://doi.org/10.1164/rccm.200304-505SO
Mammen MJ, Scannapieco FA, Sethi S. Oral‐lung microbiome interactions in lung diseases. Periodontology 2000. 2020;83(1):234-41. DOI: https://doi.org/10.1111/prd.12301
Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem. 2012;45(15):1132-44. DOI: https://doi.org/10.1016/j.clinbiochem.2012.05.034
Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Org. 2005;83:700-6.
Rohani B. Oral manifestations in patients with diabetes mellitus. World J Diabetes. 2019;10(9):485. DOI: https://doi.org/10.4239/wjd.v10.i9.485
Falcao de Oliveira Melo NS, Vieira Cavalcante da Silva RPG, Soares de Lima AA. The neonatal intubation causes defects in primary teeth of premature infants. Biomed Papers Med Faculty Palacky Univ Olomouc. 2014;158(4). DOI: https://doi.org/10.5507/bp.2013.004
Döring G, Hoiby N, Group CS. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cystic Fibrosis. 2004;3(2):67-91. DOI: https://doi.org/10.1016/j.jcf.2004.03.008
Ramsey B, Richardson MA. Impact of sinusitis in cystic fibrosis. J Allerg Clin Immunol. 1992;90(3):547-52. DOI: https://doi.org/10.1016/0091-6749(92)90183-3
Cystic Fibrosis Foundation; Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009;155(6 Suppl):S73-93. DOI: https://doi.org/10.1016/j.jpeds.2009.09.001
Al-Maskari AY, Al-Maskari MY, Al-Sudairy S. Oral manifestations and complications of diabetes mellitus: a review. Sultan Qaboos Univ Med J. 2011;11(2):179.
Mojon P. Oral health and respiratory infection. J Canad Dent Assoc. 2002;68(6):340-5.
Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, et al; Working Group on Inflammation in Cystic Fibrosis. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochim Biophys Acta. 2012;1822(5):690-713. DOI: https://doi.org/10.1016/j.bbadis.2011.12.012
Kerem E, Conway S, Elborn S, Heijerman H, Committee C. Standards of care for patients with cystic fibrosis: a European consensus. J Cystic Fibrosis. 2005;4(1):7-26. DOI: https://doi.org/10.1016/j.jcf.2004.12.002
Sermet-Gaudelus I, Bianchi ML, Garabédian M, Aris RM, Morton A, Hardin DS, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros. 2011;10 Suppl 2:S16-23. DOI: https://doi.org/10.1016/S1569-1993(11)60004-0
Saiman L, Siegel J. Infection control in cystic fibrosis. Clin Microbiol Rev. 2004;17(1):57-71. DOI: https://doi.org/10.1128/CMR.17.1.57-71.2004
Döring G, Flume P, Heijerman H, Elborn JS, Group CS. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cystic Fibrosis. 2012;11(6):461-79. DOI: https://doi.org/10.1016/j.jcf.2012.10.004